Association of adiponectin with type 2 diabetes and hypertension in African American men and women: The Jackson Heart Study

BMC Cardiovascular Disorders

Volumn 15, Issue 1, 2015, Pages

  Davis, Sharon K ^a   Gebreab, Samson Y ^a   Xu, Ruihua ^a   Riestra, Pia ^a   Khan, Rumana J ^a   Sumner, Anne E ^b   Hickson, DeMarc ^c   Bidulescu, Aurelian ^d  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^d INDIANA UNIVERSITY   (United States)

Author keywords

African Americans; Biomarkers; Hypertension; Types 2 diabetes

Indexed keywords

ADIPONECTIN; ADIPOQ PROTEIN, HUMAN; BIOLOGICAL MARKER;

ADULT; AFRICAN AMERICAN; ARTICLE; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SEX DIFFERENCE; BLOOD; CROSS-SECTIONAL STUDY; EPIDEMIOLOGY; ETHNOLOGY; MIDDLE AGED; MISSISSIPPI; MULTIVARIATE ANALYSIS; PREVALENCE; RISK FACTOR; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA;

ADIPONECTIN; AFRICAN AMERICANS; BIOMARKERS; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERTENSION; LOGISTIC MODELS; MALE; MIDDLE AGED; MISSISSIPPI; MULTIVARIATE ANALYSIS; PREVALENCE; RISK FACTORS; SEX FACTORS;

EID: 84924913117     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/s12872-015-0005-5     Document Type: Article

References (35)

1. Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med. 2002;162:1867-72.
2. Sonnenberg GE, Krakower GR, Kissebah AH. A novel pathway to the manisfestations of metablic syndrome. Obes Res. 2004;12:180-6.
3. Iwashima Y, Katsuya T, Ishikawa K, Ouchi N, Ohishi M, Sugimoto K, et al. Hypoadiponectinemia is an independent risk factor hypertension. Hypertension. 2001;43:1318-23.
4. Hug C, Lodish HF. The role of the adipocyte hormone adiponectin in cardiovascular disease. Curr Opin Pharmacol. 2005;5:129-34.
5. Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyke EJ, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins; evidence for independent roles of age and sex. Diabetologia. 2013;46:459-69.
6. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2004;24:29-33.
7. Hulver MW, Saleh O, MacDonald KG, Pories WJ, Barakat HA. Ethnic differences in adiponectin levels. Metabolism. 2004;53:1-3.
8. Buchan DS, Ollis S, Thomas NE, Simpson A, Young JD, Cooper SM, et al. Prevalence of traditional and novel markers of cardiovascular disease risk in Scottish adolescents: socioeconomic effects. Appl Physiol Nutr Metab. 2012;37:829-39.
9. Khanolkar A, Vagero D, Koupil I. Social determinants of cardiac disease biomarkers: investigating a Swedish male cohort at ages 50 and 70. Eur J Prev Cardiol. 2012;19:523-33.
10. National Center for Health Statistics. Health, United States, 2011: With special features on socioeconomic status and health. U.S. Department of Health and Human Services. Hyattsville, MD: Centers for Disease Control and Prevention; 2012.
11. Hanley A, Wagenknecht LE, Norries JM, Bergman R, Anderson A, Chen YI. Adiponectin and the incidence of type 2 diabetes in Hispanics and African Americans. Diabaetes Care. 2011;34:2231-6.
12. Wang L, Manson JE, Gaziano JM, Liu S, Cochrane B, Cook NR, et al. Plasma adiponectin and the risk of hypertension in white and black postmenopausal women. Clin Chem. 2012;58:1438-45.
13. Duncan BB, Schmidt MI, Pankow JS, Bang H, Couper D, Ballantyne CM, et al. Adiponectin and the development of type 2 diabetes: the Atherosclerosis Risk in Communities Study. Diabetes. 2004;53:2472-8.
14. Bidulescu A, Liu J, Musani SK, Fox ER, Samdarshi TE, Sarpong DF, et al. Association of adiponectin with left ventricular mass in African Americans: the Jackson heart study. Circ Heart Fail. 2011;4:747-53.
15. Bidulescu A, Liu J, Hickson DA, Hariston KG, Fox ER, Arnett DK, et al. Gender differences in the association of visceral and subcutaneous adiposity with adiponectin in African Americans: the Jackson Heart Study. BMC Cardiovasc Disord. 2013;13:9-18.
16. Bidulescu A, Liu J, Chen Z, Hickson DA, Musani SK, Samdarshi TE, et al. Associations of adiponectin and leptin with incident coronary heart disease and ischemic stroke in African Americans: the Jackson Heart Study. Frontiers in Public Health 2013; doi:10.3389/fpubh.2013.00016.
17. Taylor Jr HA. The Jackson Heart Study: an overview. Ethn Dis. 2005;15(4 suppl 6):1-3.
18. Carpenter MA, Crow R, Steffes M, Rock W, Heibraun J, Evans G, et al. Laboratory, reading center, and coordinating center data management methods in the Jackson Heart Study. Am J Med Sci. 2004;328:131-44.
19. Shand B, Elder P, Scott R, Frampton C, Willis J. Biovariability of plasma adiponectin. Clin Chem Lab Med. 2006;10:12-64. 1268.
20. Mattehews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostatsis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in men. Diabetologia. 1985;28:412-9.
21. Liu J, Butler KR, Buxbaum SG, Sung JH, Campbell BW, Taylor HA. Leptinemia and its association with stroke and coronary heart disease in the Jackson Heart Study. Clin Endocrinol (Oxf). 2009;72:32-7.
22. SAS Institute Inc., Cary, North Carolina.
23. Kanaya AM, Harris T, Goodpaster BH, Tylavsky F, Cummings SR. Health, Aging and Body Composition (ABC) Study: adipocytokines attenuate the association between visceral adiposity and diabetes in older adults. Diabetes Care. 2004;27:1375-80.
24. Combs TP, Berg AH, Rajala MW, Klebanov S, Iyengar P, Jimenez-Chillaron JC, et al. Sexual differentiation, pregnancy, calorie restriction, and aging affect the adipocyte-specific secretory protein adiponectin. Diabetes. 2003;52:268-76.
25. Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagarentai H, et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes. 2002;51:2734-41.
26. Xu A, Chen KW, Hoo RL, Wang Y, Tan KCB, Zhang J, et al. Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem. 2005;280:18073-80.
27. Asferg C, Mogelvang R, Flyvbjerg A, Frystyk J, Jensen JS, Marott JL, et al. Leptin, not adiponectin, predicts hypertension in the Copenhagen City Heart Study. Am J Hypertens. 2010;23:327-33.
28. Kamari Y, Shimoni N, Koren F, Peleg E, Sharabi Y, Grossman E. High-salt diet increases plasma adiponectin levels independent of blood pressure in hypertensive rates: the role of the renin-angiotensin-aldosterone system. J Hypertens. 2010;28:95-101.
29. Haugen E, Furukaura Y, Isic A, Fu M. Increased adiponectin level in parallel with increased NT-Pro BNP in patients with severe heart failure in the elderly: a hospital cohort study. Int J Cardiol. 2008;125:216-9.
30. Kanaya AM, Fyr CW, Vittinghoff E, Havel PJ, Matteo C, Niclas B, et al. Serum adiponectin and coronary heart disease risk in older black and white Americans. J Clin Endocrinol Metab. 2006;91:5044-50.
31. Szmitko PE, Teoh H, Stewart DJ, Verma S. Adiponectin and cardiovascular disease: state of the art? Am J Physiol Heart Circ Physiol. 2007;292:H1655-63.
32. Teoh H, Strauss MH, Szmitko PE, Verma S. Adiponectin and myocardial infaraction: a paradox or a paradigm? Eur Heart J. 2006;27:2266-8.
33. Imatoh T, Miyazaki M, Momose Y, Tanihara S, Une H. Adiponectin levels associated with the development of hypertension: a prospective study. Hypertens Res. 2008;31:229-33.
34. Waki H, Yamauchi T, Kamon J, Ito Y, Uchida S, Kita S, et al. Impaired multimerization of human adiponectin mutants associated with diabetes molecular structure and multimer formation of adiponectin. J Biol Chem. 2003;278:40352-63.
35. Glintborg D, Frystyk J, Hojlund K, Anderson KK, Henriksen JE, Hermann AP, et al. Total and high molecular weight (hmw) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placebo-controlled study in polycystic ovary syndrome. Clin Endocrinol (Oxf). 2008;68:165-74.